CBLB Deficiency in Human CD4+ T Cells Results in Resistance to T Regulatory Suppression through Multiple Mechanisms

J Immunol. 2022 Oct 1;209(7):1260-1271. doi: 10.4049/jimmunol.2200219. Epub 2022 Sep 7.

Abstract

Cbl-b is a negative regulator of T cell activation, and in murine models, a lack of Cblb results in resistance of T effector (Teff) cells to T regulatory (Treg) cells, a feature of T cells in many autoimmune diseases. Here, we used trackable gene editing approaches to knock out CBLB in primary human CD4+ T cells. We found that CBLB-knockout (CBLB-KO) CD4+ T cells were hyperproliferative and produced excessive amounts of IL-2. CBLB-KO CD4+ T cells were resistant to Treg suppression in vitro, which was partially reversed by blockade of IL-2. RNA-sequencing and puromycin incorporation assays demonstrated that CBLB-KO CD4+ T cells can overcome Treg suppression on the transcriptional and translational levels, resulting in the overproduction of cytokines to drive the proliferation and activation of Teff cells. These findings highlight a potential mechanism of Teff resistance in human autoimmune disease and the power of gene editing primary T cells to explore disease mechanisms.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adaptor Proteins, Signal Transducing / metabolism
  • Animals
  • Autoimmune Diseases* / metabolism
  • CD4-Positive T-Lymphocytes*
  • Cytokines / metabolism
  • Humans
  • Interleukin-2 / genetics
  • Interleukin-2 / metabolism
  • Mice
  • Proto-Oncogene Proteins c-cbl / genetics
  • Proto-Oncogene Proteins c-cbl / metabolism
  • Puromycin
  • RNA / metabolism
  • T-Lymphocytes, Regulatory

Substances

  • Adaptor Proteins, Signal Transducing
  • Cytokines
  • Interleukin-2
  • Puromycin
  • RNA
  • CBLB protein, human
  • Proto-Oncogene Proteins c-cbl